PHATHOM PHARMACEUTICALS, INC. Interest Expense Nonoperating
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Interest Expense Nonoperating of $15.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $15.10M, a 13.79% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $15.80M, a 12.58% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $16.42M, a 11.69% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $16.11M, a 12.85% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $68.11M, a 5.41% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $72.01M, a 71.58% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $41.97M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.10M 10-Q · filed 2026-07-30 | $30.90M 10-Q · filed 2026-07-30 | $47.32M derived: sum of 3 quarters · filed 2026-07-30 | $63.43M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $15.80M 10-Q · filed 2026-04-30 | $32.22M derived: sum of 2 quarters · filed 2026-04-30 | $48.32M derived: sum of 3 quarters · filed 2026-04-30 | $65.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $16.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $32.53M derived: sum of 2 quarters · filed 2026-02-26 | $50.05M derived: sum of 3 quarters · filed 2026-07-30 | $68.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | $16.11M 10-Q · filed 2025-10-30 | $33.63M derived: sum of 2 quarters · filed 2026-07-30 | $51.70M 10-Q · filed 2025-10-30 | $70.29M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $17.52M 10-Q · filed 2026-07-30 | $35.59M 10-Q · filed 2026-07-30 | $54.18M derived: sum of 3 quarters · filed 2026-07-30 | $72.67M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $18.07M 10-Q · filed 2026-04-30 | $36.66M derived: sum of 2 quarters · filed 2026-04-30 | $55.15M derived: sum of 3 quarters · filed 2026-04-30 | $72.91M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $18.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $37.08M derived: sum of 2 quarters · filed 2026-02-26 | $54.84M derived: sum of 3 quarters · filed 2026-02-26 | $72.01M 10-K · filed 2026-02-26 |
| 2024-09-30 | $18.48M 10-Q · filed 2025-10-30 | $36.25M derived: sum of 2 quarters · filed 2025-10-30 | $53.42M 10-Q · filed 2025-10-30 | $66.44M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $17.76M 10-Q · filed 2025-08-07 | $34.93M 10-Q · filed 2025-08-07 | $47.96M derived: sum of 3 quarters · filed 2025-08-07 | $58.07M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $17.17M 10-Q · filed 2025-05-01 | $30.20M derived: sum of 2 quarters · filed 2025-05-01 | $40.30M derived: sum of 3 quarters · filed 2025-05-01 | |
| 2023-12-31 | $13.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $23.14M derived: sum of 2 quarters · filed 2025-03-06 | $41.97M 10-K · filed 2025-03-06 | |
| 2023-09-30 | $10.11M 10-Q · filed 2024-11-07 | $28.94M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |